Method for Increasing Recombinant Protein Expression
Summary
The USPTO published patent application US20260098271A1 assigned to Hoffmann-La Roche Inc., covering a method for increasing recombinant protein expression through use of a nucleic acid encoding a selection marker, self-cleaving peptide sequence, and proteinaceous protease inhibitor. The invention aims to increase heterologous polypeptide production by reducing protease cleavage. The application was filed on May 20, 2025.
What changed
The USPTO published an international patent application (A1) for Hoffmann-La Roche Inc. covering nucleic acid constructs that combine a selection marker, self-cleaving peptide sequence, and protease inhibitor to increase recombinant protein yields. The technology addresses protease degradation issues in heterologous protein production systems.
For pharmaceutical and biotechnology companies engaged in recombinant protein manufacturing, this patent represents potential freedom-to-operate considerations for similar expression technologies. Companies should review their current protein production methods to assess whether they employ comparable nucleic acid constructs or protease inhibition strategies that may fall within this patent's scope.
What to do next
- Monitor patent database for related filings
- Review IP strategy for recombinant protein production
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHOD FOR INCREASING RECOMBINANT PROTEIN EXPRESSION
Application US20260098271A1 Kind: A1 Apr 09, 2026
Assignee
Hoffmann-La Roche Inc.
Inventors
Peter BRUENKER, Martina GEIGER, Simon AUSLAENDER, Ulrich GEOPFERT
Abstract
Herein is reported a nucleic acid comprising in operably linked form a nucleic acid encoding a selection marker, a nucleic acid encoding a self-cleaving peptide sequence, and a nucleic acid encoding a proteinaceous protease inhibitor. Further reported are methods for the recombinant production of a heterologous polypeptide using said nucleic acid as well as a cell comprising said nucleic acid according to the invention. Likewise reported is the use of the nucleic acid according to the invention for increasing the amount of the recombinantly produced heterologous polypeptide by reducing protease cleavage.
CPC Classifications
C12N 15/67 C07K 14/4703 C12N 9/1003 C12N 2830/50
Filing Date
2025-05-20
Application No.
19213865
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.